Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site | Zendy

Katie A. Howell | Zendy; Xiangguo Qiu | Zendy; Jennifer M. Brannan | Zendy; Christopher Bryan | Zendy; Edgar Davidson | Zendy; Frederick W. Holtsberg | Zendy; Anna Z. Wec | Zendy; Sergey Shulenin | Zendy; Julia E. Biggins | Zendy; R. Gordon Douglas | Zendy; Sven Enterlein | Zendy; Hannah L. Turner | Zendy; Jesper Pallesen | Zendy; Charles D. Murin | Zendy; Shihua He | Zendy; Andrea Kroeker | Zendy; Hong Vu | Zendy; Andrew S. Herbert | Zendy; Marnie L. Fusco | Zendy; Elisabeth K. Nyakatura | Zendy; Jonathan R. Lai | Zendy; ZhenYong Keck | Zendy; Steven K. H. Foung | Zendy; Erica Ollmann Saphire | Zendy; Larry Zeitlin | Zendy; Andrew B. Ward | Zendy; Kartik Chandran | Zendy; Benjamin J. Doranz | Zendy; Gary Kobinger | Zendy; John M. Dye | Zendy; M. Javad Aman | Zendy

Open Access

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site

Author(s) -

Katie A. Howell,

Xiangguo Qiu,

Jennifer M. Brannan,

Christopher Bryan,

Edgar Davidson,

Frederick W. Holtsberg,

Anna Z. Wec,

Sergey Shulenin,

Julia E. Biggins,

R. Gordon Douglas,

Sven Enterlein,

Hannah L. Turner,

Jesper Pallesen,

Charles D. Murin,

Shihua He,

Andrea Kroeker,

Hong Vu,

Andrew S. Herbert,

Marnie L. Fusco,

Elisabeth K. Nyakatura,

Jonathan R. Lai,

ZhenYong Keck,

Steven K. H. Foung,

Erica Ollmann Saphire,

Larry Zeitlin,

Andrew B. Ward,

Kartik Chandran,

Benjamin J. Doranz,

Gary Kobinger,

John M. Dye,

M. Javad Aman

Publication year - 2016

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2016.04.026

Subject(s) - ebolavirus , epitope , ebola virus , virology , antibody , monoclonal antibody , glycoprotein , biology , virus , immunology , microbiology and biotechnology

Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research